Kidney-Related Outcome in Cardiorenal Syndrome Type 3

Table 2

Distribution of predefined variables in surviving and nonsurviving patients.

Variable	Survival	Death	value
Gender (females in %)	47.1	43.6	0.79
Age (mean years+/−SD)	82.4+/−1.7	79+/−1.2	0.29
In-hospital stay (means days+/−SD)	14.9+/−2.8	22.4+/−2	0.051
AKIN stage (1/2/3 in %)	11.8/35.2/52.9	21.8/14/37.2	0.43
Initial serum creatinine (micro-Mol/L+/−SD)	143+/−281	196+/−273	0.74
Peak serum creatinine (micro-Mol/L+/−SD)	401.6+/−38.3	335.6+/−17.6	0.07 d
Serum creatinine before discharge (micro-Mol/L+/−SD)	355.7+/−45.2	189+/−12.4	<0.001
Initial serum sodium (mMol/L+/−SD)	138.3+/−1.0	137.4+/−0.5	0.81
Minimal serum sodium (mMol/L+/−SD)	136.1+/−1.2	134.9+/−0.7	0.57
Peak serum sodium (mMol/L+/−SD)	143.7+/−1.9	144.1+/−0.5	0.6
Initial serum potassium (mMol/L+/−SD)	5.2+/−0.2	4.8+/−0.1	0.2
Minimal serum potassium (mMol/L+/−SD)	4.2+/−0.2	3.6+/−0.07	0.03
Peak serum potassium (mMol/L+/−SD)	5.5+/−0.26	5.2+/−0.08	0.12
Initial NT-proBNP (pg/mL)	16,766+/−3,475	9,270+/−1,429	0.015
Peak NT-proBNP (pg/mL)	20,602+/−3,292	10,687+/−1,319	0.005
Initial CRP (mg/L+/−SD)	58+/−15.1	49.9+/−7.7	0.45
Peak CRP (mg/L+/−SD)	165.6+/−21	127.3+/−12.2	0.058
Vasopressors (%)	11.8	7.7	0.58
Invasive ventilation (%)	23.5	10.3	0.13
Arterial hypertension (%)	100	89.7	0.16
Diabetes (%)	76.5	52.6	0.07
Obesity (%)	43.8	57.7	0.3
Preexisting CHF (%)	29.4	26.9	0.83
Preexisting CAD (%)	35.3	42.3	0.59
COPD (%)	23.5	17.9	0.59
Hyperuricemia (%)	23.5	24.4	0.94
History of cancer (%)	41.2	24.4	0.15